Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
Discover
Back to filter
Show all topics (10)
Related topics
Dec 1, 2022
Cytek Cloud is the new digital ecosystem that supports full spectrum flow cytometry research from panel design to data...
See More, Sort More with Cytek Full Spectrum Systems
Nov 28, 2022
Still wondering whether to join the shift to full spectrum cytometry? Easily transfer assays from your Cytek Northern...
Demonstrate the value of RareCyte Orion system via web-based Minerva viewer
Nov 25, 2022
The HTA CRC Atlas X dataset contains images and other data being used for construction of an atlas of human colorectal...
Practical aspects of an imaging study: live in vivo scanning
Nov 11, 2022
In this webinar, MOLECUBES will present a live in vivo demonstration, showing the entire workflow from animal...
Download the newest AVATAR data presented at CAR-TCR
Oct 21, 2022
Xcell Bio CSO, James Lim, presented new data showcasing improved potency of AVATAR-expanded CAR T cells and highlighted...
RareCyte Orion system advances Multi-modal digital pathology for colorectal cancer diagnosis
Oct 19, 2022
Precision medicine is critically dependent on better methods for diagnosing and staging disease and predicting drug...
Introducing MARS system : revolutionary solution for your workflow of cell separation and enrichment
Oct 7, 2022
The MARS family of instruments provides a breakthrough solution to complete the workflow of cell separation and...
Understand the Cancer Ecosystem based on single cells analysis
Sep 22, 2022
Mission Bio is a life sciences company that accelerates discoveries and cures for a wide range of diseases by equipping...
Automating DNA Extraction for High-Throughput Bacterial Plasmid Purification with CyBi®-SELMA
Sep 19, 2022
The Need to Increase Plasmid Isolation Throughput, Challenges with Scaling up Plasmid DNA Extraction, Automating the...
Introducing RareCyte Orion, integrating Spatial Biology with Multiplex Imaging
Sep 13, 2022
Orion, the highly multiplexed fluorescent imaging system, empower investigators to unlock spatial context for key...
Preclinical PET imaging in studies of candidate therapeutics
Jun 22, 2017
Clinical and preclinical non-invasive PET imaging is employed in the development and validation of therapeutic agents for cancer and neurological disorders, and a range of other diseases. Reported studies have used numerous agents including FDG, FLT, FMISO and FAZA as early biomarkers of drug efficacy. Preclinical PET imaging has been proven in studies of therapeutic targeting and biodistribution, drug target interactions, pharmacodynamics and toxicology. These methods have helped facilitate the development of therapeutic agents that are now clinically available. Probably two of the most common uses of preclinical PET imaging in drug discovery are studies of compound targeting and biodistribution and therapeutic efficacy. In the article, you can find a brief introduction to preclinical PET imaging for such studies.
Related technologies: PET, SPECT, CT
Brand profile
